Overview

Overview
 
Immuno-oncology is aimed at destroying cancer cells by stimulating the patient's immune system without affecting healthy tissues, with the goal of delivering long-lasting responses and cure. This process is tightly regulated by interactions between receptors on immune cells that influence the immune response against cancer cells. 
 
LeadArtis has generated an array of novel drug candidates, including a tumor-targeted costimulatory MT simultaneously targeting a clinically validated tumor-associated antigen (TAA) on cancer cells and TNFR costimulatory receptors on T cells. A follow-up candidate is a T cell-recruiting bispecific antibody with the ATTACK configuration. 
 
These Trimerbodies allow us to fine tune the potency of the T cell activation and cell killing, potentially improving the tolerability of tumor immunotherapy. We have demonstrated highly effective and well-tolerated killing of target cells in a variety of assays.

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...